Introduction

Previously the substantial data on long-term treatment of humans with proton pump inhibitors (PPI) has not revealed any definite risks [1] and prolonged gastric acid suppression with PPI rarely produced adverse event [2]. Hence, Proton pump inhibitors have an excellent safety profile [3], supporting the short-and long-term safety of PPI [4]. They have been become a commonly prescribed class of drugs worldwide [3,5], long-term use of PPI is becoming more prevalent [6]. However, current evidences have demonstrated that long-term use of PPI might generate certain adverse events [3]. Thus, the viewpoints of adverse events for long-term use of proton pump inhibitors in human remain inconsistent. Moreover, studies have shown that chronic acid suppression by proton pump inhibitor therapy might lead to hypergastrinemia [7–9] and increasing enterochromafﬁn-like cell dysplasia and risk of gastric.

NET development, and progression of carcinogenesis in a certain predisposed subset of Barrett’s esophagus patients [9]. However, a contradictory conclusion did not support gastrin dependence of adenocarcinoma of the stomach or the colon and considering that it might be explained by the presence of gastrin receptors of tumour cells and the role of gastrin as an autocrine growth factor in some of these tumours [10]. Additionally, a study suggested that prolonged hypochlorhydria predisposed to gastric carcinoma by an increase in the production of carcinogenic N-nitroso compounds [11].

However, accumulated evidence [12], has shown that gastrin likely does not promote—and may even suppress—distal antral gastric cancer. Hence, these hypotheses have led to concerns about the safety of long-term PPI administration [11,13]. Particularly, whether long-term use of proton pump inhibitors in human might result in esophageal and gastrointestinal precancerous lesions or carcinoma causes the extensive concern in the clinical.

1. The associations between long-term uses of proton pump inhibitors and Barrett’s esophagus, esophageal Gastroesophageal reﬂux disease (GERD) is a risk factor for the development of Barrett’s esophagus and esophageal adenocarcinoma. Current evidences have conﬁrmed that long-term use of PPI seems to be a safe and efﬁcient treatment for GERD [14,15] and Barrett’s oesophagus [16]. Long-term acid suppression reduced proliferation in Barrett’s esophagus samples [17] and may reduce esophageal adenocarcinoma (EAC) by a minimum of 19% [18]. Use of ongoing PPI therapy appeared beneﬁcial in the prevention of dysplasia and adenocarcinoma in patients with Barrett’s oesophagus [19]. Although PPI treatment over 1–13 years did not shorten the Barrett’s oesophagus segment but squamous islands appeared in many patients, and, the incidence of oesophageal adenocarcinoma received proton pump inhibitor–treated patients was low 20]. Hence, PPI use was associated with a decreased incidence of neoplasia in Barrett’s esophagus [21], supporting a cancer-protective role for PPI in patients with Barrett’s esophagus.
2. The association between long-term uses of proton pump inhibitors and polyposis, gastric carcinoma, gastric neuroendocrine tumors

Gland Polyps (FGPs) is an important precancerous lesions of gastric carcinoma. Whether long-term use of PPI might increase or decrease the incidence of FGPs remains a consistent conclusion. Studies have revealed that long-term use of PPI was a particularly strong risk factor [24,25]. Among them, PPI have been linked to gastric fundal polyposis and not antral gland polyposis [26]. Another report originating from an Asian country showed that fundal Gland Polyps (FGPs) in the corpus of stomach were significantly higher than the fundus in a patient of long-term PPI therapy [27]. There was a causal relation between the use of omeprazole and the development of fundic gland polyposis in patients without H. pylori gastritis [28].

Gastric polyps and nodules might be found in children receiving long-term omeprazole therapy during the mean observation period of 31 months [29]. Long-term use of proton pump inhibitors may be associated with the presence of small gastric fundic gland polyps and hyperplastic polyps [30]. But, the opposite research results showed that sporadic FGPs may not be induced by PPI therapy [31]. For instance, the prevalence of FGPs and polyps number were not link with omeprazole therapy [32]. Furthermore, long-term use of PPI did not influence the frequency, growth, or histology of adenomatous polyposis [33]. Long-term use of PPI was associated with a reduction in both baseline and interval development of hyperplastic polyps [33]. Hence, whether long-term use of PPI might cause FGPs is inconsistent, it still need to further confirm that whether there are the associations between long-term use of PPI and FGPs.

Whether long-term use of PPI might result in gastric carcinoma development remains controversial. Long-term use of PPI was related to increased risk of gastric cancer [34], via stimulation of DNA–damaged cells; and, increased risk of periampullary cancers [35], via long-lasting iatrogenic hypergastrinemia induced by potent inhibitors of acid secretion. Additionally, human gastric carcinomas of diffuse type, particularly the signet–ring subtype, showed ECL cell differentiation, suggesting involvement of gastrin in the carcinogenesis [36]. However, recent study indicated no association between PPI use and the risk of gastric cancers [8]. There are tremendous reports does not support the above viewpoints, which long-term inhibition of the gastric proton pump did not increase the risk of gastric cancer because of antioxidant depletion [37]; there are no evidence that pantoprazole as a longer acting PPI conferred an excess risk of gastric cancer, other gastrointestinal cancers or all cancers compared with other shorter-acting PPI [38]. There has even study suggested that anti-carcinogenic actions of PPI were augmented with PPI–induced hypergastrinemia [39]. But, recently a multicenter study confirmed that elevated lesions and cobblestone–like mucosa were characteristic endoscopic features in PPI users. And, a gender–associated difference was noted in terms of the frequency of these lesions [40]; another study results [41], pointed to a major influence of reverse causation and confounding by indication on the association between PPI use and gastric cancer incidence, the finding of increased incidence among PPI users with most prescriptions and longest follow-up warrants further investigation. In addition, PPI intake was associated with the existence and epidemiological relevance of gastric neuroendocrine tumors (g–NETs) [42,43], illustrating a patient with a poorly differentiated neuroendocrine carcinoma with ECL cell characteristics probably induced by hypergastrinemia secondary to long-term use of PPI [42]. There were reports indicating development of ECL cell carcinoids after long-term treatment with proton pump inhibitors [43] and hypergastrinemia secondary to PPI treatment might induce enterochromaffin–like cell carcinoids in man [44,45]. Additionally, based on few case reports showed although PPI-induced hypergastrinemia has the potential to stimulate hyperplasia of enterochromaffin–like (ECL) cells, however, the role was very weak, considering Physicians have to continue PPI prescription without any fear about the occurrence of this adverse event [46]. However, Children with long-term use of PPI did not appear to develop atrophic gastritis or carcinoid tumours [47]. In short, whether long-term use of PPI might result in gastric carcinoma development and carcinoid tumours need to be verified by large prospective studies.

3. The association between long-term use of proton pump inhibitors and colorectal cancer,

Enormous researches have indicated no association between long-term use of PPI at a regular dose and the increase in risk of colorectal cancer [8,48–52]. However, only a previously study suggested that PPI use might be modestly associated with CRC risk [53,54]. According to the results of the present majority studies, the conclusion seem to support the opinions, which long-term use of PPI does not increase in risk of colorectal cancer. Further research should needed to confirm the lock of a risk–increasing effect of long-term use of PPI.

**Conclusion**

Patients with GERD and Barrett’s oesophagus should be encouraged to continue long term use of PPI therapy as a preventive measures for oesophageal adenocarcinoma. However, whether long-term use of PPI may cause FGPs and gastric carcinoma development remains are inconsistent. long-term treatment with PPI might cause gastric neuroendocrine tumours (g–NETs) and the development of ECL cell carcinoids. The presently study’s conclusion seem to support that long-term use of PPI does not increase in risk of colorectal cancer. Hence, Physicians must weigh potential risks of long-term use of PPI against therapeutic benefit. The continued follow-up of patients taking PPI for extended periods will provide greater experience regarding the potential gastrointestinal adverse effects of long-term acid suppression.
References

1. Yeomans ND, Dent J (2000) Personal review: alarmism or legitimate concerns about long-term suppression of gastric acid secretion? Aliment Pharmacol Ther 14: 267-271. Link: https://goo.gl/T02a11

2. Laine L, Ahnen D, McClain C, Solcia E, Walsh JH (2014) Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 14: 651-668. Link: https://goo.gl/1NhH5k

3. Sheen E, Triadafilopoulos G (2011) Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 56: 931-950. Link: https://goo.gl/eSPkKZ

4. Garrett WR (1998) Considerations for long-term use of proton-pump inhibitors. Am J Health Syst Pharm 55: 2268-2279. Link: https://goo.gl/bYJWtg

5. Ali T, Roberts DN, Tierney WM (2009) Long-term safety concerns with proton pump inhibitors. Am J Med 122: 896-903. Link: https://goo.gl/CfNYWd

6. Roulet L, Vernaz N, Giostra E, Gasche Y, Desmeules J (2012) Adverse effects of proton pump inhibitors: should we worry about long-term exposure? Rev Med Interne 33: 439-445. Link: https://goo.gl/ybUbVv

7. McCoy RF, Arnold R, Bardhan KD, Cattan D, Klinkenberg-Knol E, et al. (1995) Pathophysiological effects of long-term acid suppression in man. Dig Dis Sci 40: 965-1205. Link: https://goo.gl/NKtU06

8. Mathieu N (2008) Risk of long-term treatment with proton pump inhibitors. Rev Prat 58: 1451-1454. Link: https://goo.gl/GppPzEh

9. Ko Y, Tang J, Sanagappali S, Kim BS, Leong RW (2016) Safety of proton pump inhibitors and risk of gastric cancers: review of literature and pathophysiological mechanisms. Expert Opin Drug Saf 15: 53-63. Link: https://goo.gl/nzxM7r

10. Creutzfeldt W, Lamberts R (1991) Is hypergastrinaemia dangerous to man? Scand J Gastroenterol Suppl 180: 179-191. Link: https://goo.gl/t2z5Qj

11. Moncur PH, Heatley RV (2000) Safety of proton-pump inhibitors: the acid test. Eur J Gastroenterol Hepatol 12: 145-147. Link: https://goo.gl/4EkUv

12. Hayakawa Y, Chang W, Jin G, Wang TC (2006) Gastrin and upper GI cancers. Curr Opin Pharmacol 6: 31-37. Link: https://goo.gl/T0Xv66

13. McCarthy DM (2010) Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol 26: 624-63. Link: https://goo.gl/Rf56cb

14. Pohle T, Domschke W (2000) Results of short-and long-term medical treatment of gastroesophageal reflux disease (GERD). Langenbecks Arch Surg 385: 317-323. Link: https://goo.gl/I0F7FzEh

15. Lada MJ, Nieman DR, Han M, Timratana P, Alsalahi O, et al. (2013) Fundic gland polyps and association with proton pump inhibitor intake: a prospective study in 1,780 endoscopies. Dig Dis Sci 56: 1743-1748. Link: https://goo.gl/tbHg1H

16. Alqutub AN, Masoodi I (2010) A case of gastric polyposis in antral area of stomach following prolonged proton pump therapy. Med Sci 8: 19. Link: https://goo.gl/Ds58s3

17. Young J, Abbas Z, Jafari W, Ahmad Z (2008) Gastric corpus polyps associated with Proton Pump Inhibitors therapy. J Coll Physicians Surg Pak 18: 172-173. Link: https://goo.gl/noosJ5

18. Funderholm R, Ege-Hansen J, Rindt WC, Blichert-Toft M (1996) Gastric polyps and association with proton pump inhibitor therapy and the development of dysplasia in patients with Barrett’s oesophagus. Med J Aust 180: 387-391. Link: https://goo.gl/CC6HkB

19. Cooper BT, Chapman W, Neumann CS, Gearty JC (2006) Continuous treatment of Barrett’s oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Aliment Pharmacol Ther 23: 727-733. Link: https://goo.gl/46OUpJ

20. Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC (2004) Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett’s oesophagus. Med J Aust 180: 387-391. Link: https://goo.gl/CC6HkB

21. Spechler SJ (2014) Does Barrett’s esophagus regress after surgery (or proton pump inhibitors)? Dig Dis Sci 32: 156-163. Link: https://goo.gl/tbXeUX

22. Dunbar KB, Souza RF, Spechler SJ (2015) The Effect of Proton Pump Inhibitors on Barrett’s Esophagus. Gastroenterol Clin North Am 44: 415-424. Link: https://goo.gl/gepLdJ

23. Hvid-Jensen F, Pedersen L, Funch-Jensen P, Dreyes AM (2014) Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett’s oesophagus: a nationwide study of 9883 patients. Aliment Pharmacol Ther 39: 984-991. Link: https://goo.gl/wEK7CU

24. Huang CZ, Lai RX, Mai L, Zhou HL, Chen HJ, et al. (2014) Relative risk factors associated with the development of fundal gland polyps. Eur J Gastroenterol Hepatol. 26: 1217-1221. Link: https://goo.gl/27VnXn

25. Zelter A, Fernández JL, Bilder C, Rodríguez P, Wonaga A, et al. (2011) Fundic gland polyps and association with proton pump inhibitor intake: a prospective study in 1,780 endoscopies. Dig Dis Sci 56: 1743-1748. Link: https://goo.gl/tbHg1H

26. Choudhry U, Boyce HW Jr, Coppola D (1998) Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol 110: 615-621. Link: https://goo.gl/9RMdZ

27. Alqutub AN, Masoodi I (2010) A case of gastric polyposis in antral area of stomach following prolonged proton pump therapy. Med Sci 8: 19. Link: https://goo.gl/noosJ5

28. el-Zimaity HM, Jackson FW, Graham DY (1997) Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol 92: 1858-1860. Link: https://goo.gl/eZHd66

29. Pashankar DS, Israel DM (2002) Gastric polyps and nodules in children receiving long-term omeprazole therapy. J Pediatr Gastroenterol Nutr 35: 658-662. Link: https://goo.gl/wzuRGU

30. Tavani V, Tavani E, Ferrara A, Caruso S, Bellone S (2005) Sporadic fundic gland polyps: clinico-pathologic features and associated diseases. Pol J Pathol 56: 131-137. Link: https://goo.gl/EZ7TSR

31. Cao H, Qu R, Zhang Z, Kong X, Wang S, et al. (2014) Sporadic fundic gland polyps are not associated with proton pump inhibitors therapy but negatively correlate with Helicobacter pylori infection in China. Chin Med J 127: 1239-1243. Link: https://goo.gl/hoHHwh

32. Declich P, Tavani E, Ferrara A, Caruso S, Bellone S (2005) Sporadic fundic gland polyps: clinico-pathologic features and associated diseases. Pol J Pathol 56: 131-137. Link: https://goo.gl/ez7TSR

33. Singh M, Dhindsa G, Friedland S, Triadafilopoulos G (2007) Long-term use of proton pump inhibitors does not affect the frequency, growth, or histologic characteristics of colon adenomas. Aliment Pharmacol Ther 26: 1051-1061. Link: https://goo.gl/6UVgJG

34. Wulf DM, Gustafsson B, Fossmark R, Ovgistad G (2005) Antilulcer drugs and gastric cancer. Dig Dis Sci 50: 539-44. Link: https://goo.gl/BLaKbd

35. Chien LN, Huang YJ, Shao YH, Chang CJ, Chuang MT, et al. (2016) Proton pump inhibitors and risk of peripapillary cancers–A nested case-control study. Int J Cancer 138: 1401-1409. Link: https://goo.gl/avpoK
36. Waldum HL, Hauso Ø, Fossmark R (2014) The regulation of gastric acid secretion - clinical perspectives. Acta Physiol (Oxf) 210: 239-256. Link: https://goo.gl/BkzuwA

37. White KL, Chalmers DM, Martin IG, Everett SM, Neville PM, et al. (2002) Dietary antioxidants and DNA damage in patients on long-term acid-suppression therapy: a randomized controlled study. Br J Nutr 88: 265-271. Link: https://epi421

38. Schneider JL, Kolitsopoulos F, Corley DA (2016) Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors. Aliment Pharmacol Ther 43: 73-82. Link: https://goo.gl/YRRv7H

39. Han YM, Park JM, Kangwan N, Jeong M, Lee S, et al. (2015) Role of proton pump inhibitors in preventing hypergastrinemia-associated carcinogenesis and in antagonizing the trophic effect of gastrin. J Physiol Pharmacol 66: 159-167. Link: https://goo.gl/bS9Bgp

40. Kiso M, Ito M, Boda T, Kotachi T, Masuda K, et al. (2017) Endoscopic findings of the gastric mucosa during long-term use of proton pump inhibitor - a multicenter study. Scand J Gastroenterol 9: 1-5. Link: https://goo.gl/nkriDBt

41. Poulsen AH, Christensen S, McLaughlin JK, Thomsen RW, Sørensen HT, et al. (2009) Proton pump inhibitors and risk of gastric cancer: a population-based, case-control study. Gastroenterology 133: 755-760. Link: https://goo.gl/CsgzSz

42. Jianu CS, Lange OJ, Viset T, Qvigstad G, Martenssen TC, et al. (2012) Carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol 47: 64-67. Link: https://goo.gl/hqAzT

43. Cavalcoli F, Zilli A, Conte D, Ciafardini C, Massironi S (2015) Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence? Scand J Gastroenterol 50: 1197-1203. Link: https://goo.gl/CHBvZE

44. García Rodríguez LA, Lagergren J, Lindblad M (2006) Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut 55: 1538-1544. Link: https://goo.gl/zwMwkw

45. Jianu CS, Fossmark R, Viset T, Qvigstad G, Sardal O, et al. (2012) Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther 36: 644-649. Link: https://goo.gl/vWg1J0

46. Jianu CS, Fossmark R, Viset T, Qvigstad G, Sardal O, et al. (2012) Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther 36: 644-649. Link: https://goo.gl/vWg1J0

47. Savarino V, Dulbecco P, Savarino E (2016) Are proton pump inhibitors really so dangerous? Dig Liver Dis 48: 851-859. Link: https://goo.gl/FOWVV

48. Hassall E, Owen D, Kerr W, Sturby T, Richardson P, et al. (2011) Gastric histology in children treated with proton pump inhibitors long term, with emphasis on enterochromaffin cell-like hyperplasia. Aliment Pharmacol Ther 33: 829-836. Link: https://goo.gl/pFKMx6

49. Freeman HJ (2008) Proton pump inhibitors and an emerging epidemic of gastric fundic gland polyposis. World J Gastroenterol 14: 1318-1320. Link: https://goo.gl/5qen7

50. Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, et al. (2007) Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology 133: 755-760. Link: https://goo.gl/CsgzSz

51. Freeman HJ (2008) Proton pump inhibitors and an emerging epidemic of gastric fundic gland polyposis. World J Gastroenterol 14: 1318-1320. Link: https://goo.gl/mTDYVF

52. van Soest EM, van Rossum LG, Dieleman JP, van Dijen MG, Siersema PD, et al. (2008) Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol 103: 966-973. Link: https://goo.gl/AtYzF0

53. Yang YX, Hennessy S, Propert K, Hwang WT, Sedarat A, et al. (2007) Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology. 133: 748-754. Link: https://goo.gl/2D6HRM

54. Chubak J, Boudreau DM, Rulyak SJ, Mandelson MT (2009) Colorectal cancer risk in relation to use of acid suppressive medications. Pharmacoepidemiol Drug Saf 18: 540-544. Link: https://goo.gl/s3bCvZ

Copyright: © 2017 Baoge QU, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Baoge QU, Hao QU (2017) Influence of Long-Term Use of Proton Pump Inhibitors on Esophageal and Gastrointestinal Precancerous Lesions or Carcinoma. Arch Clin Gastroenterol 3(2): 027-032. DOI: http://doi.org/10.17352/2455-2283.000034